Predictive value of improvement in the immune tumour microenvironment in patients with breast cancer treated with neoadjuvant chemotherapy

被引:30
|
作者
Goto, Wataru [1 ]
Kashiwagi, Shinichiro [1 ]
Asano, Yuka [1 ]
Takada, Koji [1 ]
Takahashi, Katsuyuki [2 ]
Hatano, Takaharu [3 ]
Takashima, Tsutomu [1 ]
Tomita, Shuhei [2 ]
Motomura, Hisashi [3 ]
Ohsawa, Masahiko [4 ]
Hirakawa, Kosei [1 ]
Ohira, Masaichi [1 ]
机构
[1] Osaka City Univ, Dept Surg Oncol, Grad Sch Med, Osaka, Japan
[2] Osaka City Univ, Dept Pharmacol, Grad Sch Med, Osaka, Japan
[3] Osaka City Univ, Dept Plast & Reconstruct Surg, Grad Sch Med, Osaka, Japan
[4] Osaka City Univ, Dept Diagnost Pathol, Grad Sch Med, Osaka, Japan
关键词
PATHOLOGICAL COMPLETE RESPONSE; INFILTRATING LYMPHOCYTES; PROGNOSTIC IMPACT; SYSTEMIC THERAPY; RECOMMENDATIONS; EXPRESSION; TRASTUZUMAB; CONSENSUS; SURVIVAL; MARKER;
D O I
10.1136/esmoopen-2017-000305
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Tumour-infiltrating lymphocytes (TILs) can be used to monitor the immune tumour microenvironment (iTME) and predict treatment response and outcome in breast cancer. We evaluated the prognostic significance of the levels of CD8(+) TILs and forkhead box protein (FOXP3)-positive TILs before and after neoadjuvant chemotherapy (NAC). Patients and methods We examined 136 patients with breast cancer treated with NAC. The number of CD8(+) TILs and FOXP3(+) TILs in biopsy specimens and residual tumours was evaluated by immunohistochemistry. Results Patients with a high rate of change in the CD8/FOXP3 ratio (CFR) had significantly better recurrence-free survival (RFS) (p<0.001, log-rank). In multivariate analysis, the rates of change in the CD8(+) TIL levels and the CFR were independent predictors for RFS (HR=2.304, p=0.036 and HR=4.663, p<0.001). In patients with triple-negative and hormone receptor-positive breast cancer, the rate of change in the CFR was an independent predictor for RFS (HR=13.021, p=0.002 and HR=4.377, p=0.003). Conclusion Improvement in the iTME following NAC is correlated with good outcome. The rate of change in the CFR may be a useful biomarker to predict prognosis of patients treated with NAC.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Predictive value of the improvement in tumor microenvironment for progression in breast cancer patients treated with neoadjuvant chemotherapy
    Goto, W.
    Kashiwagi, S.
    Asano, Y.
    Takada, K.
    Takahashi, K.
    Noda, S.
    Takashima, T.
    Onoda, N.
    Tomita, S.
    Hirakawa, K.
    Ohira, M.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 : 172 - 172
  • [2] Predictive value of microenvironment for progression in breast cancer patients treated with neoadjuvant chemotherapy
    Goto, Wataru
    Kashiwagi, Shinichiro
    Asano, Yuka
    Takada, Koji
    Takahashi, Katsuyuki
    Noda, Satoru
    Takashima, Tsutomu
    Onoda, Naoyoshi
    Tomita, Shuhei
    Hirakawa, Kosei
    Ohira, Masaichi
    [J]. CANCER SCIENCE, 2018, 109 : 123 - 123
  • [3] Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy
    Aas, T
    Geisler, S
    Eide, GE
    Haugen, DF
    Varhaug, JE
    Bassoe, AM
    Thorsen, T
    Berntsen, H
    Borresen-Dale, AL
    Akslen, LA
    Lonning, PE
    [J]. EUROPEAN JOURNAL OF CANCER, 2003, 39 (04) : 438 - 446
  • [4] The breast cancer immune microenvironment is modified by neoadjuvant chemotherapy
    Uruena, Claudia
    Lasso, Paola
    Bernal-Estevez, David
    Rubio, Diego
    Salazar, Ana Janeth
    Olaya, Mercedes
    Barreto, Alfonso
    Tawil, Mauricio
    Torregrosa, Lilian
    Fiorentino, Susana
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)
  • [5] The breast cancer immune microenvironment is modified by neoadjuvant chemotherapy
    Claudia Urueña
    Paola Lasso
    David Bernal-Estevez
    Diego Rubio
    Ana Janeth Salazar
    Mercedes Olaya
    Alfonso Barreto
    Mauricio Tawil
    Lilian Torregrosa
    Susana Fiorentino
    [J]. Scientific Reports, 12
  • [6] Circulating tumour cells as prognosis predictive markers of neoadjuvant chemotherapy-treated breast cancer patients
    Cui, Zhaoqing
    Su, Fengbo
    Li, Yang
    Yang, Dawei
    [J]. JOURNAL OF CHEMOTHERAPY, 2020, 32 (06) : 304 - 309
  • [7] Predictive Biomarkers in Breast Cancer: Their Value in Neoadjuvant Chemotherapy
    Fuksa, L.
    Micuda, S.
    Grim, J.
    Ryska, A.
    Hornychova, H.
    [J]. CANCER INVESTIGATION, 2012, 30 (09) : 663 - 678
  • [8] Predictive Role of Tumour-Stroma Ratio (TSR) in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Validation Study
    Zsofia, K.
    Kulka, J.
    Tokes, A. M.
    [J]. JOURNAL OF PATHOLOGY, 2021, 255 : S50 - S50
  • [9] Predictive value of survivin alternative transcript expression in locally advanced breast cancer patients treated with neoadjuvant chemotherapy
    Boidot, Romain
    Vegran, Frederique
    Lizard-Nacol, Sarab
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2009, 23 (02) : 285 - 291
  • [10] Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy
    Loibl, Sibylle
    Mueller, Berit Maria
    von Minckwitz, Gunter
    Schwabe, Michael
    Roller, Marc
    Darb-Esfahani, Silvia
    Ataseven, Beyhan
    du Bois, Andreas
    Fissler-Eckhoff, Annette
    Gerber, Bernd
    Kulmer, Uwe
    Alles, Jens-Uwe
    Mehta, Keyur
    Denkert, Carsten
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2011, 130 (02) : 477 - 487